KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incyte (INCY) Non-Current Deferred Tax Liability (2013 - 2015)

Incyte posted quarterly Non-Current Deferred Tax Liability of $9.7 million for Q3 2015, up 1153.16% year-on-year from $775000.0 in Q3 2014, and up 25.72% on a QoQ basis from $7.7 million in Q2 2015.

Incyte (INCY) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $9.7 million in Q3 2015.

  • For the quarter ending Q3 2015, Non-Current Deferred Tax Liability rose 1153.16% year-over-year to $9.7 million; the trailing twelve-month figure through Sep 2015 stood at $9.7 million (up 1153.16% YoY), and the FY2014 full-year result was $19.6 million, up 2094.53% from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2015 stood at $9.7 million, up from $7.7 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $19.6 million in Q4 2014 and bottomed at $775000.0 in Q3 2014.
  • The 3-year median for Non-Current Deferred Tax Liability is $3.5 million (2014), against an average of $5.8 million.
  • The widest annual swing landed in 2014, when Non-Current Deferred Tax Liability surged 2094.53%; it then jumped 575.45% in 2015.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $895000.0 in 2013, then soared by 2094.53% to $19.6 million in 2014, then plunged by 50.55% to $9.7 million in 2015.
  • The last three Non-Current Deferred Tax Liability figures came in at $9.7 million (Q3 2015), $7.7 million (Q2 2015), and $6.0 million (Q1 2015), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2015 9.71 Mn
Sep 30, 2015 9.71 Mn
Jun 30, 2015 7.73 Mn
Jun 30, 2015 7.73 Mn
Mar 31, 2015 6.03 Mn
Mar 31, 2015 6.03 Mn
Dec 31, 2014 19.64 Mn
Dec 31, 2014 19.64 Mn
Sep 30, 2014 775,000.00
Sep 30, 2014 775,000.00
Jun 30, 2014 900,000.00
Jun 30, 2014 900,000.00
Mar 31, 2014 892,000.00
Mar 31, 2014 892,000.00
Dec 31, 2013 895,000.00
Dec 31, 2013 895,000.00